Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 33%; Here Are 20 Stocks Moving Premarket

by | Feb 23, 2026 | General

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rose sharply in pre-market trading after the company reported the FDA approval of BYSANTI™ (milsaperidone) for the treatment of bipolar I disorder and schizophrenia – a new chemical entity opening new horizons in psychiatric innovation.

Vanda Pharmaceuticals shares jumped 33% to $7.65 in the pre-market trading session.

Here are some other stocks moving in pre-market trading.

Gainers

  • Tian Ruixiang Holdings Ltd (NASDAQ:TIRX) gained 104.2% to $0.090 in pre-market trading after dipping 15% on Friday. TIAN RUIXIANG, last week, announced a 1-for-50 reverse share split.
  • Venhub Global Inc (NASDAQ:VHUB) gained 40.7% to $2.80 in pre-market trading after falling 33% on Friday.
  • Signing Day Sports Inc (NYSE:SGN) gained 23.1% to $0.64 in pre-market trading after adding around 25% on Friday. Signing Day Sports, last week, announced effectiveness of its Form S-4 registration statement on a business combination agreement with BlockchAIn.
  • Brand Engagement Network Inc (NASDAQ:BNAI) gained 21.8% to $23.13 in pre-market trading. Brand Engagement Network recently announced the termination of its $50 million standby equity purchase agreement with YA II PN.
  • Psyence Biomedical Ltd (NASDAQ:PBM) gained 20% to $3.00 in pre-market trading. Psyence BioMed announced exercise of put option by PsyLabs and Strategic Equity Investment.
  • Primech Holdings Ltd (NASDAQ:PMEC) rose 19.7% to $0.85 in pre-market trading after gaining 7% on Friday.
  • Kaixin Holdings (NASDAQ:KXIN) rose 14.4% to $0.63 in pre-market trading after falling over 8% on Friday.
  • Rackspace Technology, Inc. (NASDAQ:RXT) gained 11.4% to $1.87 in pre-market trading after surging 37% on Friday. The company, last week, announced a strategic partnership with data-giant Palantir Technologies, Inc. (NASDAQ:PLTR), designed to accelerate deployment of Palantir’s Foundry and Artificial Intelligence Platform (AIP).
  • MoonLake Immunotherapeutics (NASDAQ:MLTX) surged 9.6% to $20.57 in pre-market trading. MoonLake reported Phase 2 S-OLARIS data showing sonelokimab achieved 80%+ ASAS40 response in axial spondyloarthritis with PET/MRI imaging confirming deep tissue inflammation reduction.

Losers

  • iPower Inc (NASDAQ:IPW) fell 16% to $2.73 in pre-market trading after the company reported second-quarter results. iPower posted a quarterly loss of $1.08 per share, versus a year-ago profit of 30 cents per share.
  • Knorex Ltd (NYSE:KNRX) dipped 14.1% to $1.40 in pre-market trading after falling 32% on Friday. KNOREX recently announced the launch of its agentic AI-ready Ads API to power cross-channel advertising automation.
  • AIOS Tech Inc (NASDAQ:AIOS) fell 13.4% to $0.53 in pre-market trading after surging 37% on Friday.
  • Ensysce Biosciences Inc (NASDAQ:ENSC) shares dipped 10.2% to $0.36 in pre-market trading.
  • Rubico Inc (NASDAQ:RUBI) fell 9.9% to $1.19 in pre-market trading after dipping 26% on Friday.
  • Blue Hat Interactv Entrtnmnt Technlgy (NASDAQ:BHAT) dipped 9.8% to $0.10 in pre-market trading. Blue Hat Interactive Entertainment Technology shares dipped around 74% on Friday after pricing a $6.4 million public offering that adds new shares and warrants.
  • SS Innovations International Inc (NASDAQ:SSII) tumbled 8.5% to $4.42 in pre-market trading after gaining 10% on Friday.
  • HomesToLife Ltd (NASDAQ:HTLM) fell 8% to $2.09 in pre-market trading after gaining 24% on Friday.
  • Novo Nordisk A/S (NYSE:NVO) declined 8% to $43.60 in pre-market trading after the company disclosed headline results from REDEFINE 4, an open-label phase 3 trial from the global REDEFINE clinical trial programme.
  • Smurfit WestRock PLC (NYSE:SW) fell 6.4% to $45.62 in pre-market trading. Smurfit WestRock recently posted downbeat quarterly results.

Photo via Shutterstock